Interferon- and complement-related MSigDB gene sets upregulated at the time of TA-TMA diagnosis in autologous HSCT recipients as compared with pretransplant baseline
| Pathway . | Direction of change and FDR . |
|---|---|
| Interferon pathways | |
| Browne interferon responsive genes | ↑ 3.59e-37 |
| Hallmark interferon-α response | ↑ 1.38e-38 |
| Bosco interferon induced antiviral module | ↑ 5.16e-27 |
| Zhang interferon response | ↑ 3.75e-18 |
| Control vs interferon-treated macrophages | ↑ 1.98e-17 |
| Moserle interferon response | ↑ 6.36e-17 |
| Chiang liver cancer subclass interferon up | ↑ 4.17e-16 |
| Reactome interferon α β signaling | ↑ 1.30e-14 |
| Reactome interferon signaling | ↑ 6.00e-12 |
| Interferon-β response up | ↑ 1.19e-11 |
| Urosevic response to imiquimod | ↑ 2.68e-11 |
| Interferon-α response up | ↑ 2.69e-10 |
| Interferon-γ response up | ↑ 6.23e-07 |
| Natsume response to interferon β | ↑ 8.02e-06 |
| Farmer breast cancer cluster | ↑ 1.94e-05 |
| Reactome γ interferon signaling | ↑ 3.87e-05 |
| Geiss response to DSRNA up | ↑ 4.13e-04 |
| VSIRF Q6 | ↑ 0.001 |
| VSICSBP Q6 | ↑ 0.004 |
| Interferon-γ biosynthetic process | ↑ 0.005 |
| VsIRF7 01 | ↑ 0.006 |
| Regulation of interferon-γ biosynthetic process | ↑ 0.01 |
| Interferon-γ production | ↑ 0.01 |
| Complement pathways | |
| Initial triggering of complement | ↑ 2.7e-105 |
| Classical complement pathway | ↑ 1.6e-102 |
| Complement pathway | ↑ 6.35e-85 |
| Complement cascade | ↑ 6.4e-59 |
| Complement and coagulation cascades | ↑ 2.2e-44 |
| Complement | ↑ 2.1e-30 |
| Lectin-induced complement pathway | ↑ 0.0008 |
| Regulation of complement cascade | ↑ 0.001 |
| Pathway . | Direction of change and FDR . |
|---|---|
| Interferon pathways | |
| Browne interferon responsive genes | ↑ 3.59e-37 |
| Hallmark interferon-α response | ↑ 1.38e-38 |
| Bosco interferon induced antiviral module | ↑ 5.16e-27 |
| Zhang interferon response | ↑ 3.75e-18 |
| Control vs interferon-treated macrophages | ↑ 1.98e-17 |
| Moserle interferon response | ↑ 6.36e-17 |
| Chiang liver cancer subclass interferon up | ↑ 4.17e-16 |
| Reactome interferon α β signaling | ↑ 1.30e-14 |
| Reactome interferon signaling | ↑ 6.00e-12 |
| Interferon-β response up | ↑ 1.19e-11 |
| Urosevic response to imiquimod | ↑ 2.68e-11 |
| Interferon-α response up | ↑ 2.69e-10 |
| Interferon-γ response up | ↑ 6.23e-07 |
| Natsume response to interferon β | ↑ 8.02e-06 |
| Farmer breast cancer cluster | ↑ 1.94e-05 |
| Reactome γ interferon signaling | ↑ 3.87e-05 |
| Geiss response to DSRNA up | ↑ 4.13e-04 |
| VSIRF Q6 | ↑ 0.001 |
| VSICSBP Q6 | ↑ 0.004 |
| Interferon-γ biosynthetic process | ↑ 0.005 |
| VsIRF7 01 | ↑ 0.006 |
| Regulation of interferon-γ biosynthetic process | ↑ 0.01 |
| Interferon-γ production | ↑ 0.01 |
| Complement pathways | |
| Initial triggering of complement | ↑ 2.7e-105 |
| Classical complement pathway | ↑ 1.6e-102 |
| Complement pathway | ↑ 6.35e-85 |
| Complement cascade | ↑ 6.4e-59 |
| Complement and coagulation cascades | ↑ 2.2e-44 |
| Complement | ↑ 2.1e-30 |
| Lectin-induced complement pathway | ↑ 0.0008 |
| Regulation of complement cascade | ↑ 0.001 |